{"id":"NCT01697592","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","officialTitle":"A Phase III, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blinded Study and Subsequent Open-label, Extension Study to Assess the Safety and Efficacy of Addition of MK-3102 in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Oral Antihyperglycemic Agent Monotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10-24","primaryCompletion":"2014-05-08","completion":"2014-05-08","firstPosted":"2012-10-02","resultsPosted":"2015-10-29","lastUpdate":"2018-09-10"},"enrollment":585,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Omarigliptin","otherNames":[]},{"type":"DRUG","name":"Matching placebo to omarigliptin","otherNames":[]}],"arms":[{"label":"Omarigliptin 25 mg/Sulfonylureas (SUs) (Phase A+B)","type":"EXPERIMENTAL"},{"label":"Omarigliptin 25 mg/Glinides (Phase A+B)","type":"EXPERIMENTAL"},{"label":"Omarigliptin 25 mg/biguanides (BGs) (Phase A+B)","type":"EXPERIMENTAL"},{"label":"Omarigliptin 25 mg/Thiazolidinediones (TZDs) (Phase A+B)","type":"EXPERIMENTAL"},{"label":"Omarigliptin 25 mg/α-GIs (Phase A+B)","type":"EXPERIMENTAL"},{"label":"Placebo/SUs (Phase A) → Omarigliptin 25 mg/SUs (Phase B)","type":"PLACEBO_COMPARATOR"},{"label":"Placebo/Glinides (Phase A) → Omarigliptin 25 mg/Gln. (Phase B)","type":"PLACEBO_COMPARATOR"},{"label":"Placebo/BGs (Phase A) → Omarigliptin 25 mg/BGs (Phase B)","type":"PLACEBO_COMPARATOR"},{"label":"Placebo/TZDs (Phase A) → Omarigliptin 25 mg/TZDs (Phase B)","type":"PLACEBO_COMPARATOR"},{"label":"Placebo/α-GIs (Phase A) → Omarigliptin 25 mg/α-GIs (Phase B)","type":"PLACEBO_COMPARATOR"}],"summary":"This study will examine the safety and efficacy of the addition of omarigliptin in Japanese participants with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and oral antihyperglycemic agent monotherapy.","primaryOutcome":{"measure":"Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue During Phase A","timeFrame":"Up to 24 weeks","effectByArm":[{"arm":"Omarigliptin 25 mg/SU (Phase A)","deltaMin":59.5,"sd":null},{"arm":"Omarigliptin 25 mg/Gln (Phase A)","deltaMin":53.8,"sd":null},{"arm":"Omarigliptin 25 mg/BG (Phase A)","deltaMin":54.5,"sd":null},{"arm":"Omarigliptin 25 mg/TZD (Phase A)","deltaMin":60,"sd":null},{"arm":"Omarigliptin 25 mg/α-GI (Phase A)","deltaMin":50.7,"sd":null},{"arm":"Placebo/SU (Phase A)","deltaMin":60.3,"sd":null},{"arm":"Placebo/Gln. (Phase A)","deltaMin":52.9,"sd":null},{"arm":"Placebo/BG (Phase A)","deltaMin":63.6,"sd":null},{"arm":"Placebo/TZD (Phase A)","deltaMin":52.9,"sd":null},{"arm":"Placebo/α-GI (Phase A)","deltaMin":53.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28589493"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":126},"commonTop":["Nasopharyngitis","Back pain","Hypoglycaemia","Bronchitis","Constipation"]}}